文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

2021年10月3日至2022年12月24日美国24个司法管辖区≥12岁未接种与接种新冠疫苗者按二价加强针接种及接种时间的发病率和死亡率

COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2023-02-10

美国24个司法管辖区分析≥12岁人群新冠发病与死亡比,比较未接种与接种者按二价加强针接种及接种时间。在BA.4/BA.5晚期,未接种者死亡RR=14.1、感染RR=2.8(对比二价接种者),死亡RR=5.4、感染RR=2.5(对比仅单价接种者);二价加强针对死亡提供额外保护,老年人保护恢复最高。

要点

  • BA.4/BA.5晚期,未接种者较二价接种者死亡RR=14.1、感染RR=2.8。
  • 同期末接种者较仅单价接种者死亡RR=5.4、感染RR=2.5。
  • 65-79岁未接种者较二价加强针者死亡RR=23.7,≥80岁为10.3。

核心结论

  • 与未接种者相比,接种二价加强针者在单价剂量或单价加强针基础上对死亡提供额外保护,老年人保护恢复最高。
  • 所有≥12岁人群应保持新冠疫苗接种最新状态,包括符合条件者接种二价加强针,以降低重症新冠风险。

研究设计与样本

  • 基于美国24个司法管辖区≥12岁人群,估计新冠病例和死亡率比(RR),比较未接种与接种者按总体接种及加强针接种时间(单价或二价),覆盖Delta和Omicron亚系(BA.1、BA.2、早期BA.4/BA.5、晚期BA.4/BA.5)优势期。

主要发现

  • BA.4/BA.5晚期,未接种者较二价接种者死亡RR=14.1、感染RR=2.8;未接种者较仅单价接种者死亡RR=5.4、感染RR=2.5。
  • 65-79岁未接种者较二价加强针者死亡RR=23.7、较单价加强针者8.3;≥80岁分别为10.3和4.2。
  • 按接种时间分层,未接种者较2周-2月内接种单价加强针者死亡相对率从Delta期RR=50.7降至早期BA.4/BA.5期7.4。
  • 早期BA.4/BA.5期,接种单价加强针后6-8月RR=4.6、9-11月4.5、≥12月2.5。
  • 晚期BA.4/BA.5期,前2周-2月内接种二价加强针者较未接种者死亡RR=15.2。

临床怎么用

  • 所有≥12岁人群应保持新冠疫苗接种最新状态,包括符合条件者接种二价加强针,以降低重症新冠风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

On September 1, 2022, CDC recommended an updated (bivalent) COVID-19 vaccine booster to help restore waning protection conferred by previous vaccination and broaden protection against emerging variants for persons aged ≥12 years (subsequently extended to persons aged ≥6 months).* To assess the impact of original (monovalent) COVID-19 vaccines and bivalent boosters, case and mortality rate ratios (RRs) were estimated comparing unvaccinated and vaccinated persons aged ≥12 years by overall receipt of and by time since booster vaccination (monovalent or bivalent) during Delta variant and Omicron sublineage (BA.1, BA.2, early BA.4/BA.5, and late BA.4/BA.5) predominance.† During the late BA.4/BA.5 period, unvaccinated persons had higher COVID-19 mortality and infection rates than persons receiving bivalent doses (mortality RR = 14.1 and infection RR = 2.8) and to a lesser extent persons vaccinated with only monovalent doses (mortality RR = 5.4 and infection RR = 2.5). Among older adults, mortality rates among unvaccinated persons were significantly higher than among those who had received a bivalent booster (65-79 years; RR = 23.7 and ≥80 years; 10.3) or a monovalent booster (65-79 years; 8.3 and ≥80 years; 4.2). In a second analysis stratified by time since booster vaccination, there was a progressive decline from the Delta period (RR = 50.7) to the early BA.4/BA.5 period (7.4) in relative COVID-19 mortality rates among unvaccinated persons compared with persons receiving who had received a monovalent booster within 2 weeks-2 months. During the early BA.4/BA.5 period, declines in relative mortality rates were observed at 6-8 (RR = 4.6), 9-11 (4.5), and ≥12 (2.5) months after receiving a monovalent booster. In contrast, bivalent boosters received during the preceding 2 weeks-2 months improved protection against death (RR = 15.2) during the late BA.4/BA.5 period. In both analyses, when compared with unvaccinated persons, persons who had received bivalent boosters were provided additional protection against death over monovalent doses or monovalent boosters. Restored protection was highest in older adults. All persons should stay up to date with COVID-19 vaccination, including receipt of a bivalent booster by eligible persons, to reduce the risk for severe COVID-19.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022. MMWR Morb Mortal Wkly Rep. 2023. PMID: 36757865. doi:10.15585/mmwr.mm7206a3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。